Reviewing Dare Bioscience (DARE) and Its Competitors

Dare Bioscience (NASDAQ: DARE) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Dare Bioscience to related businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability.

Analyst Recommendations

This is a summary of recent ratings for Dare Bioscience and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dare Bioscience 0 0 0 0 N/A
Dare Bioscience Competitors 1134 3426 11925 240 2.67

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.66%. Given Dare Bioscience’s rivals higher probable upside, analysts plainly believe Dare Bioscience has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Dare Bioscience and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Dare Bioscience $760,000.00 -$39.30 million -1.04
Dare Bioscience Competitors $290.27 million $35.99 million 55.49

Dare Bioscience’s rivals have higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Dare Bioscience and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dare Bioscience N/A -228.18% -126.97%
Dare Bioscience Competitors -5,443.85% -164.39% -36.43%

Risk and Volatility

Dare Bioscience has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500. Comparatively, Dare Bioscience’s rivals have a beta of 2.37, meaning that their average stock price is 137% more volatile than the S&P 500.

Insider and Institutional Ownership

8.1% of Dare Bioscience shares are owned by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 28.6% of Dare Bioscience shares are owned by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Dare Bioscience rivals beat Dare Bioscience on 7 of the 10 factors compared.

About Dare Bioscience

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with's FREE daily email newsletter.

Leave a Reply